World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
120
Citations
70729
World Ranking
3682
National Ranking
2025

Christopher J. Logothetis publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Christopher J. Logothetis sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 708 publications — 81st percentile

81% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Christopher J. Logothetis D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Christopher J. Logothetis sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 120 D-Index — 82nd percentile

82% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Christopher J. Logothetis is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily focuses on fields related to Medicine, with significant contributions to Biochemistry, Genetics and Molecular Biology. Within these fields, their work spans subfields such as Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Molecular Biology, and Radiology, Nuclear Medicine and Imaging.

The main topics explored in their research include Prostate Cancer Treatment and Research, Prostate Cancer Diagnosis and Treatment, Cancer, Lipids, and Metabolism, Radiopharmaceutical Chemistry and Applications, Bone health and treatments, Bladder and Urothelial Cancer Treatments, and Cancer Immunotherapy and Biomarkers.

Christopher J. Logothetis has published extensively in several leading scientific venues. Frequent publication venues include:

  • Journal of Clinical Oncology
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Cancer Research
  • European Urology
  • Clinical Cancer Research

Notable recent papers authored or co-authored by Logothetis include:

  • Assessment of Luminal and Basal Phenotypes in Bladder Cancer, 2020, Scientific Reports
  • Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors, 2020, European Urology
  • Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy, 2022, Nature
  • Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022, 2022, European Urology
  • The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development, 2020, Clinical Cancer Research

The scientist frequently collaborates with others in their field. Their frequent co-authors include:

  • Paul G. Corn
  • Ana M. Aparicio
  • Sumit K. Subudhi
  • Patricia Troncoso
  • Eleni Efstathiou

Best Publications

  • Abiraterone and Increased Survival in Metastatic Prostate Cancer

    Johann S. de Bono;Christopher J. Logothetis;Arturo Molina;Karim Fizazi

  • The Immune Landscape of Cancer

    Vésteinn Thorsson;David L Gibbs;Scott D Brown;Denise Wolf

  • Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

    Charles J. Ryan;Matthew R. Smith;Johann S. De Bono;Arturo Molina

  • Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

    Eugene D. Kwon;Charles G. Drake;Howard I. Scher;Karim Fizazi

  • Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

    Howard I. Scher;Michael J. Morris;Walter M. Stadler;Celestia Higano

  • Prostate cancer. Clinical practice guidelines in oncology.

    James Mohler;Robert R. Bahnson;Barry Boston;J. Erik Busby

  • Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

    Karim Fizazi;Howard I. Scher;Arturo Molina;Christopher J. Logothetis

  • Genomic and Functional Approaches to Understanding Cancer Aneuploidy

    Alison M. Taylor;Alison M. Taylor;Juliann Shih;Gavin Ha;Gavin Ha;Galen F. Gao

  • Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

    Charles J. Ryan;Matthew R. Smith;Karim Fizazi;Fred Saad

  • Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade

    Vivek K. Arora;Emily Schenkein;Rajmohan Murali;Sumit K. Subudhi

  • Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer

    Tomasz M. Beer;Eugene D. Kwon;Charles G. Drake;Karim Fizazi

  • Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci

    Fredrick R. Schumacher;Ali Amin Al Olama;Sonja I. Berndt;Sara Benlloch

  • Pathogenic Germline Variants in 10,389 Adult Cancers

    Kuan-Lin Huang;R Jay Mashl;Yige Wu;Deborah I Ritter

  • Steps toward mapping the human vasculature by phage display

    Wadih Arap;Mikhail G. Kolonin;Martin Trepel;Johanna Lahdenranta

  • A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors.

    Christopher J. Logothetis;Francisco H. Dexeus;Laury Finn;Avishay Sella

  • Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study

    Sameek Roychowdhury;Matthew K. Iyer;Dan R. Robinson;Robert J. Lonigro

  • CTLA-4 blockade increases IFNγ-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

    Chrysoula I. Liakou;Ashish Kamat;Derek Ng Tang;Hong Chen

  • Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017

    Silke Gillessen;Gerhardt Attard;Tomasz M Beer;Himisha Beltran

  • VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer

    Jianjun Gao;John F. Ward;Curtis A. Pettaway;Lewis Zhichang Shi

  • Phase I Trial of the Proteasome Inhibitor Bortezomib in Patients With Advanced Solid Tumors With Observations in Androgen-Independent Prostate Cancer

    Christos N. Papandreou;Danai D. Daliani;Darrell Nix;Hong Yang

Frequent Co-Authors

Patricia Troncoso
Patricia Troncoso The University of Texas MD Anderson Cancer Center
Karim Fizazi
Karim Fizazi University of Paris-Saclay
Curtis A. Pettaway
Curtis A. Pettaway The University of Texas MD Anderson Cancer Center
Gary E. Gallick
Gary E. Gallick The University of Texas MD Anderson Cancer Center
Louis L. Pisters
Louis L. Pisters The University of Texas MD Anderson Cancer Center
Xuemei Wang
Xuemei Wang The University of Texas MD Anderson Cancer Center
Howard I. Scher
Howard I. Scher Memorial Sloan Kettering Cancer Center
Fred Saad
Fred Saad University of Montreal
Johann S. de Bono
Johann S. de Bono Institute of Cancer Research
David E. Neal
David E. Neal University of Cambridge

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine opens the door to numerous online degree programs and pathways, each catering to different backgrounds and goals. For registered nurses who want to advance their qualifications without stepping away from work, affordable rn to bsn programs are a popular choice, allowing RNs to earn their Bachelor of Science in Nursing conveniently and at a lower cost.

Those with a non-nursing bachelor's degree who are eager for a rapid entry into nursing may find direct entry msn online options particularly attractive. These programs let students accelerate toward becoming nurse practitioners or leaders without previous nursing credentials.

Accessibility also matters. Students looking for less competitive admissions can consider some of the easiest nursing programs to get into, which offer more flexible entry requirements, making a career in nursing more attainable for many.

Beyond nursing, allied health careers such as medical billing and coding provide essential opportunities. Students interested in flexible study options and financial support can explore the financial aid for medical billing and coding online classes, enabling a pathway into the healthcare industry without the need for clinical practice.

Best Scientists Citing Christopher J. Logothetis

Trending Scientists

Recently Published Articles